Idexx Laboratories price target lowered to $730 from $750 at UBS

UBS analyst Andrea Alfonso lowered the firm’s price target on Idexx Laboratories (IDXX) to $730 from $750 and keeps a Neutral rating on the shares. The print showed mixed signals, with early benefits from increased diagnostic use among aging “pandemic puppies” and pricing strength helping maintain a premium, but Q4 also raised concerns around muted Q1 growth, a softer 2026 gross margin outlook, and slower inVue placements in Year 2, the analyst tells investors in a research note. With macro headwinds and fewer near-term margin expansion drivers, the risk/reward appears balanced pending clearer evidence that recent pricing premiums are sustainable, the firm says.